Prof. Dr. Olaf G. Wilhelm
Chief Executive Officer
WILEX AG - Research and development of smallmolecule drugs for autoimmune diseases and cancer
The therapeutic agent RENCAREX® (INN: Girentuximab) is a targeted antibody for the treatment of solid tumours. The antibody Girentuximab binds to the CA IX antigen expressed on the tumour cells, thereby triggering an immune reaction called Antibody-Dependent Cellular Cytotoxicity (ADCC). Through this mechanism, effector cells, e.g. NK (natural killer) cells, of the immune system are activated to kill the tumour cells.